APONTIS PHARMA Announces CEO Departure Amid Company Transition

APONTIS PHARMA AG has announced that CEO Bruno Wohlschlegel will step down at the end of August 2025 upon the conclusion of his contract. Wohlschlegel, appointed in September 2023, played a pivotal role in restructuring the company and restoring its profitability. He will remain as an advisor to assist in the leadership transition until the end of September.

Under Wohlschlegel's leadership, APONTIS PHARMA achieved significant milestones, implementing a successful performance and efficiency improvement program and returning to growth in 2024. Additionally, the pharmaceutical company Zentiva placed a public purchase offer for APONTIS PHARMA’s shares, with shareholders approving a merger squeeze-out, effectively integrating it into Zentiva Group.

Matthias Wiedenfels, Chairman of the Supervisory Board, lauds Wohlschlegel's contributions, emphasizing the successful execution of the restructuring plan. APONTIS PHARMA’s integration into Zentiva marks a new chapter, as the trading of its shares is set to end following this merger.